Mechanism and clinical application of thymosin in the treatment of lung cancer

被引：5

作者：

Liu, Yafeng ^{[1
]}

Lu, Jibin ^{[1
]}

机构：

[1] China Med Univ, Dept Thorac Surg, Shengjing Hosp, Shenyang, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷

关键词：

thymosin; lung cancer; therapy; thymosin alpha 1; thymalfasin; thymopentin; immunotherapy; RADIATION PNEUMONITIS; ANTITUMOR-ACTIVITY; ENHANCED RECOVERY; ALPHA-1; CELLS; BETA-4; MIGRATION; INVASION; THERAPY; IMPACT;

D O I：

10.3389/fimmu.2023.1237978

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer is one of the leading causes of death worldwide. The burden of cancer on public health is becoming more widely acknowledged. Lung cancer has one of the highest incidence and mortality rates of all cancers. The prevalence of early screening, the emergence of targeted therapy, and the development of immunotherapy have all significantly improved the overall prognosis of lung cancer patients. The current state of affairs, however, is not encouraging, and there are issues like poor treatment outcomes for some patients and extremely poor prognoses for those with advanced lung cancer. Because of their potent immunomodulatory capabilities, thymosin drugs are frequently used in the treatment of tumors. The effectiveness of thymosin drugs in the treatment of lung cancer has been demonstrated in numerous studies, which amply demonstrates the potential and future of thymosin drugs for the treatment of lung cancer. The clinical research on thymosin peptide drugs in lung cancer and the basic research on the mechanism of thymosin drugs in anti-lung cancer are both systematically summarized and analyzed in this paper, along with future research directions.

引用

页数：12

共 96 条

[1] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[3] Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview [J].

Ashraf-Uz-Zaman, Md ;

Bhalerao, Aditya ;

Mikelis, Constantinos M. ;

Cucullo, Luca ;

German, Nadezhda A. .

CANCERS, 2020, 12 (05)

[4] Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS) [J].

Batchelor, Timothy J. P. ;

Rasburn, Neil J. ;

Abdelnour-Berchtold, Etienne ;

Brunelli, Alessandro ;

Cerfolio, Robert J. ;

Gonzalez, Michel ;

Ljungqvist, Olle ;

Petersen, Rene H. ;

Popescu, Wanda M. ;

Slinger, Peter D. ;

Naidu, Babu .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2019, 55 (01) :91-115

[5] Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial [J].

Becker, Nikolaus ;

Motsch, Erna ;

Trotter, Anke ;

Heussel, Claus P. ;

Dienemann, Hendrik ;

Schnabel, Philipp A. ;

Kauczor, Hans-Ulrich ;

Maldonado, Sandra Gonzalez ;

Miller, Anthony B. ;

Kaaks, Rudolf ;

Delorme, Stefan .

INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (06) :1503-1513

[6] Thymosin α1 suppresses migration and invasion o f PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling [J].

Bo, Cong ;

Wu, Qiang ;

Zhao, Hai ;

Li, Xuebing ;

Zhou, Qinghua .

ONCOTARGETS AND THERAPY, 2018, 11 :7255-7270

[7] Thymosin α1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo [J].

Bozza, Silvia ;

Gaziano, Roberta ;

Bonifazi, Pierluigi ;

Zelante, Teresa ;

Pitzurra, Lucia ;

Montagnoli, Claudia ;

Moretti, Silvia ;

Castronari, Roberto ;

Sinibaldi, Paola ;

Rasi, Guido ;

Garaci, Enrico ;

Bistoni, Francesco ;

Romani, Luigina .

INTERNATIONAL IMMUNOLOGY, 2007, 19 (11) :1261-1270

[8] Lung Cancer Chemotherapy, New Treatment and Related Patents [J].

Cheepsattayakorn, Attapon ;

Cheepsattayakorn, Ruangrong .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2014, 9 (03) :372-381

[9] The role of ROS in tumour development and progression [J].

Cheung, Eric C. ;

Vousden, Karen H. .

NATURE REVIEWS CANCER, 2022, 22 (05) :280-297

[10] A Reappraisal of Thymosin Alpha1 in Cancer Therapy [J].

Costantini, Claudio ;

Bellet, Marina M. ;

Pariano, Marilena ;

Renga, Giorgia ;

Stincardini, Claudia ;

Goldstein, Allan L. ;

Garaci, Enrico ;

Romani, Luigina .

FRONTIERS IN ONCOLOGY, 2019, 9

← 1 2 3 4 5 6 7 8 9 10 →